This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of XELOX With Cetuximab in Advanced Gastric Cancer

This study has been completed.
Information provided by (Responsible Party):
Yoon-Koo Kang, Asan Medical Center Identifier:
First received: November 9, 2006
Last updated: July 13, 2017
Last verified: July 2017
The combination of capecitabine and oxaliplatin as 'backbone' regimen, adding a newer biologic agent, cetuximab, is a reasonable strategy of further chemotherapy development in advanced gastric cancer, which is the investigators study rationale.

Condition Intervention Phase
Gastric Cancer Drug: Capecitabine, Oxaliplatin, Cetuximab Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Phase II Study of Cetuximab (Erbitux®) in Combination With XELOX [XELoda® (Capecitabine) and OXaliplatin] in Patients With Advanced Gastric Cancer

Resource links provided by NLM:

Further study details as provided by Yoon-Koo Kang, Asan Medical Center:

Primary Outcome Measures:
  • Overall Response Rate [ Time Frame: 6 months ]
    Tumor response was evaluated every two cycles by CT scans and other indicated methods, and the patients with complete or partial response required a confirmatory response evaluation at least 4 weeks later. Patients without confirmatory evaluation were not regarded as responders.

Secondary Outcome Measures:
  • Progression-free Survival [ Time Frame: 1 year ]
  • Overall Survival [ Time Frame: 1 year ]
  • Toxicity Profile [ Time Frame: 1 years ]
    Number of patients who experienced toxicity from study treatment to evaluate the safety and tolerability of XELOX plus Cetuximab

Enrollment: 44
Study Start Date: November 2006
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Capecitbine, oxaliplatin, cetuximab
Capecitbine, oxaliplatin and cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
Drug: Capecitabine, Oxaliplatin, Cetuximab
Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
Other Name: xeloda, oxalitin, Erbitux

Detailed Description:

There is presently no chemotherapy regimen considered to be the global standard of care for patients with AGC, and there is still a need for new agents and/or regimens to improve the efficacy and safety of chemotherapy in advanced stomach cancers.

The combination of 5-fluorouracil plus cisplatin (FP) has been widely used for the first-line treatment of advanced gastric cancer in many countries.

Randomized phase III trial investigating capecitabine plus cisplatin(XP) versus FP showed XP is at least as good as FP with improved patients' preference.

A Phase II study of capecitabine plus oxaliplatin (XELOX) was conducted in our study group.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Having given signed written informed consent
  • Patients must have histologically or cytologically documented stomach adenocarcinoma including adenocarcinoma of the esophagogastric junction.
  • Patients must have unresectable metastatic disease or recurrent disease after curative surgical resection with uni-dimensionally measurable disease according to RECIST (at least longest diameter 1 cm on computed tomography scan, or at least 2 cm on chest x-ray or physical examination
  • Age 18 to 70 years old
  • Estimated life expectancy of more than 3 months
  • ECOG performance status < 2 (See Appendix E)
  • Adequate bone marrow function (WBC>3,000/µL, ANC>1,500/µL, and platelets>100,000/µL, Hb>8g/dl)
  • Adequate kidney function (creatinine<1.5 mg/dL)
  • Adequate liver function [bilirubin< 2.0 mg/dL, transaminases levels<3 times the Upper Normal Value (5 times for patients with liver metastasis)]
  • Prothrombin time not less than 50% of Lower Normal Value
  • No prior chemotherapy
  • No prior radiation therapy
  • Patients must not have psychological, familial, sociological or geographical conditions which do not permit medical follow-up and compliance with this study.
  • Women of childbearing potential must have a negative serum HCG pregnancy test on admission. Men and women of reproductive potential must have agreed to use an effective method of contraception while on treatment and for 6 months after study treatment.

Exclusion Criteria:

  • Past or concurrent history of neoplasm other than gastric adenocarcinoma within the last five years, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri.
  • Central nervous system (CNS) metastases.
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start
  • Gastric outlet obstruction, intestinal obstruction and obvious peritoneal seeding.
  • Evidence of serious gastrointestinal bleeding.
  • The patient has bony lesions as the sole evaluable disease.
  • Pregnant or lactating women, women of childbearing potential not employing adequate contraception.
  • Patients with sensory neuropathy (grade> 1 according to NCI CTCAE v. 3.0).
  • Hypersensitivity to any of the study drugs or ingredients.
  • Other serious illness or medical conditions that would not allow study participation in the best interest of the patient as decided by the investigator.
  • Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry.
  • History of significant neurologic or psychiatric disorders including dementia or seizures.
  • Active uncontrolled infection.
  • Pre-existing clinically significant diarrhea.
  • Unstable diabetes mellitus.
  • Severe hypercalcemia of > 12 mg/dL and uncontrolled with bisphosphonates.
  • Active disseminated intravascular coagulation.
  • Concurrent treatment with corticosteroids (or equivalent) except as use for the prophylactic medication regimen, treatment of acute hypersensitivity reactions or nausea, or unless chronic treatment (initiated > 6 months prior to study entry) at low dose (<20 mg methyl prednisolone or equivalent).
  • Concomitant or administration of any other experimental drug under investigation within 4 weeks before the study.
  • Concomitant or previous hormonal therapy, or immunotherapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00398398

Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of
Korea Cancer Center Hospital
Seoul, Korea, Republic of
Seoul Samsung Medical Center
Seoul, Korea, Republic of
Sponsors and Collaborators
Asan Medical Center
Principal Investigator: Yoon-Koo Kang, MD, PhD Asan Medical Center
  More Information

Responsible Party: Yoon-Koo Kang, Professor, Asan Medical Center Identifier: NCT00398398     History of Changes
Other Study ID Numbers: AMC-ONCGI-0603
EMR 62202-723,OXALI_L_01600
Study First Received: November 9, 2006
Results First Received: December 15, 2013
Last Updated: July 13, 2017

Keywords provided by Yoon-Koo Kang, Asan Medical Center:
gastric cancer

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on September 21, 2017